Having identified the mechanism by which NAP1L1 p.D349E promotes cardiac hypertrophy by triggering cGAS-STING-IFN signaling, we investigated whether cardiac hypertrophy could be prevented by pharmacologically inhibiting cGAS-STING-IFN signaling in mice through the use of the selective STING antagonist C-176 or the IFNAR1 antibody HY-P99137 (Fig. 5A). The gene discussed is NAP1L1; the disease is cardiac hypertrophy.